Charles River Laboratories International, Inc. (CRL) Dividend History

Charles River Laboratories International, Inc. is a global research and development organization specializing in providing essential products and services for the pharmaceutical, biotechnology, and healthcare industries. Founded in 1947, the company offers early-stage contract research, preclinical and clinical support, and laboratory services to assist in the discovery, development, and manufacturing of new drugs and therapies. Its facilities and expertise enable clients to streamline drug development processes and meet regulatory requirements efficiently.

251 Ballardvale St, Wilmington, MA, 01887
Phone: 781-222-6000

Dividend History

Charles River Laboratories International, Inc. currently does not pay dividends

Company News

  • Global Bioanalytical Testing Services Market to Observe Stunning Growth at a CAGR of ~16% by 2032 | DelveInsight

    The bioanalytical testing services market is experiencing substantial growth, driven by increasing chronic and infectious diseases, rising demand for biopharmaceuticals, and expanded R&D in biologics and advanced therapies. North America is expected to dominate the market, with significant technological advancements and strategic collaborations fueling expansion.

    GlobeNewswire Inc.
  • Charles River (CRL) Q2 EPS Jumps 11%

    Charles River Laboratories reported Q2 2025 earnings with revenue of $1,032.1 million, slightly up 0.6% year-over-year. Non-GAAP EPS was $3.12, beating analyst expectations, but the company faced challenges with organic revenue decline and segment-specific performance issues.

    The Motley Fool
  • Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

    Charles River Laboratories reported Q2 earnings with revenue of $1.03 million, slightly up 0.6% year-over-year. The company raised its fiscal year 2025 earnings guidance and noted minimal impact from government funding reductions and biotech market conditions.

    Benzinga
  • The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

    The S&P 500 has faced a turbulent start to 2025, with the index down 8% year-to-date. The two worst-performing stocks, Deckers (DECK) and Charles River Laboratories (CRL), have declined 47% and 42% respectively due to tariffs and regulatory changes. Analysts remain cautiously optimistic on DECK but uncertain about CRL's long-term prospects.

    Investing.com
    Featured Companies: DECK
  • Charles River's (CRL) RMS Growth Aids Amid FX Headwind

    Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

    Zacks Investment Research
    Featured Companies: HIMS MEDP RMD

Related Companies

Page data last updated 09/06/2025 07:33:52 UTC